Epidemiology and Treatment Trends of Rheumatoid Arthritis with Dementia in Japan: A Nationwide Claims Database Study

Eisai Co., Ltd.,0 个研究点目标入组 450,000 人开始时间: 待定最近更新: 2025年4月28日

适应症

试验速览

暂无简介。

•Patients had to fulfill all of the following criteria to be included in the study: aged >=65 years at the time of RA diagnosis between 1 January 2015 and 31 December 2023 (ICD-10 codes M05, M060, M062, M063, M068, M069, excluding RS3PE syndrome [standard injury code: 8844120], wrist deformity [standard injury code: 8845190], and ulnar deviation [standard injury code: 8845158]); with at least one prescription for a DMARD or oral glucocorticoid within 1 year of the first RA diagnosis; and with a record of data in the DeSC database for at least 180 days prior to the index date.

•No exclusion criteria were set for the primary study endpoint. For secondary endpoints, individuals who lacked prescription records for DMARDs or oral corticosteroids within 1 year of the index date were excluded.

prevalence of dementia

时间窗: 2015-2023

The prevalence of dementia in all patients with RA aged >=65 years

annual incidence of dementia in patients with RA aged 65-74 and >=75 years(annual)
status of DMARD prescriptions in patients with RA aged 65-74 and >=75 years who developed dementia
survival time analysis for new prescriptions or increased doses of oral glucocorticoids in patients aged 65-74 and >=75 years who developed dementia

发起方

Eisai Co., Ltd.,